Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers successfully inhibit spread of cancer in mice

05.06.2003


Many types of cancer--like those of the breast and prostate--would not be nearly as deadly if it weren’t for their ability to spread to vital organs. Still, scientists don’t yet fully understand the way in which cancer spreads, or metastasizes, or how to prevent the process.



Now, researchers at the San Francisco VA Medical Center (SFVAMC) have used a modified version of a naturally occurring human protein to decrease the spread of human breast cancer implanted in mice.

"We were able to significantly reduce the spread of the disease and decrease tumor growth without any evidence of toxicity," said senior author Gary Jarvis, PhD, a SFVAMC microbiologist and UCSF associate professor of laboratory medicine.


The current findings appear in the June issue of Clinical Cancer Research, with figures from the paper appearing on its cover.

Jarvis credits first author Constance John, PhD, a research chemist in his lab at the time, with coming up with the idea of interfering with the ability of cancer cells to stick to one another as a way of attacking metastasis. The ability to adhere to other cells is what allows a cell that breaks away from a primary tumor to lodge in other parts of the body.

"It’s when tumors spread to essential organs, such as the liver or lung, that they become fatal. There is nothing to date that has been approved by the FDA for treatment of cancer that works on that process," said John.

John, who is no longer affiliated with SFVAMC, is currently the president of MandalMed, Inc., a San Francisco-based company working to develop a drug that inhibits metastasis based on these findings. (Jarvis, of SFVAMC/UCSF, has no financial stake in MandalMed.)

A drug that could reduce metastasis would greatly improve upon the beneficial outcomes already achieved with chemotherapy, surgery and radiation, John said. "We’re not trying to develop a cure for cancer. What we’re trying to do is make cancer a disease that one can live with," she said.

As a way of targeting metastasis, John proposed modifying a human protein known as galectin-3, a member of the family of proteins called lectins that bind to sugar molecules on the surfaces of cells. Galectin-3 is known to play multiple roles in cancer formation, including the promotion of cell-to-cell adhesion, or sticking. "The idea was to break that contact and inhibit secondary cancer formation," Jarvis said.

The researchers left the sugar-binding region of galectin-3 intact, but removed the part of the protein that normally allows cells to stick to one another. They then implanted portions of human-derived breast cancer tumors into the chest pads of nude mice, mice having a low-functioning immune system. Once the tumors were established, they injected the experimental animals with truncated galectin-3. The control mice were given sham injections.

By the end of the experiment, the team found that cancer had spread to lymph nodes or other organs in four out of 20 experimental mice versus 11 of 20 control mice. In addition, the post-treatment growth of the implanted tumor fragments was significantly less than in the control animals. Monitoring the animals during this and additional experiments showed that the modified protein did not cause any apparent adverse effects or death in the mice.

Jarvis believes that the modified version of galectin-3 was able to interfere with the breast cancer cells’ ability to stick to one another and to the healthy cells of other organs. "The data supports the hypotheses that truncated galectin-3 inhibits the process of metastasis," he said.

Jarvis and his colleagues at the SFVAMC are currently working on the functional studies that would determine the mechanism behind the reduction in metastasis they observed.

Jarvis said a drug therapy targeting galectin-3 activity might someday be effectively used in combination with currently available cancer medications. "If we can stop metastasis in humans, we will have gone a long way towards successfully treating cancer," he said.

Jarvis and his colleagues at the SFVAMC have since repeated these results and plan to extend the current study by looking at different types of cancer and different truncated versions of galectin-3 in combination with currently available anticancer medications.


Additional authors on the paper include Hakon Leffler, MD, PhD, Barbro Kahl-Knutsson and Inga Svensson of the Institute of Laboratory Medicine at Lund University in Lund, Sweden.

This research was supported by a grant to the Northern California Institute for Research and Education (NCIRE) from the U.S. Department of the Army Breast Cancer Research Program. Based at the SFVAMC, NCIRE is the largest congressionally sanctioned research foundation. The Swedish Medical Research Council also provided support.

Statement of financial disclosure: Neither UCSF, SFVAMC nor Gary Jarvis, PhD, has a financial stake in MandalMed, Inc. Constance John, PhD, serves as president of MandalMed, Inc., but was employed as a research chemist in Jarvis’ laboratory at the time this research was conducted.

Camille Mojica | EurekAlert!
Further information:
http://www.ucsf.edu/

More articles from Health and Medicine:

nachricht Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

nachricht Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Black nitrogen: Bayreuth researchers discover new high-pressure material and solve a puzzle of the periodic table

29.05.2020 | Materials Sciences

Argonne researchers create active material out of microscopic spinning particles

29.05.2020 | Materials Sciences

Smart windows that self-illuminate on rainy days

29.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>